IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?

被引：133

作者：

Perrier, Stephane

Darakhshan, Froogh

Hajduch, Eric ^{[1
]}

机构：

[1] INSERM, U755 Nutrion, F-75006 Paris, France

[2] Univ Paris 06, F-75005 Paris, France

[3] Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland

来源：

FEBS LETTERS | 2006年 / 580卷 / 27期

关键词：

interleukin-1 receptor antagonist; diabetes; obesity; insulin resistance; gene polymorphism; adipocyte;

D O I：

10.1016/j.febslet.2006.10.061

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin-1 receptor antagonist (IL-1ra) has been shown to play a crucial role in the prevention of various inflammatory diseases. There is also convincing evidence that IL-1ra is able to counteract inflammatory effects of IL-1 members implicated in insulin resistance and diabetes. However, the use of knock-out animal models provides evidence to the contrary and the role of IL-1ra in obesity-linked anomalies remains controversial. This minireview gets an insight into recent findings on the implication of IL-1ra and its gene polymorphism in diabetes and obesity, discusses the potential dual effects of IL-1ra observed in different models, and comments on future directions. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：6289 / 6294

页数：6

共 74 条

[1] The balance between IL-1 and IL-1Ra in disease [J].